9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The coexistence of papillary thyroid carcinoma, anaplastic thyroid carcinoma (squamous cell carcinoma subtype) and poorly differentiated thyroid carcinoma: a case report

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Papillary thyroid carcinoma (PTC) accounts for about 60% of adult thyroid carcinoma and generally has an excellent prognosis. Primary squamous cell carcinoma of thyroid (PSCCT) is a rare thyroid tumor with high malignancy and poor prognosis. In 2022, the 5 th edition of World Health Organization (WHO) has classified it as a subtype of anaplastic thyroid carcinoma (ATC), abbreviated as ATC-squamous cell carcinoma (SCC) subtype. Poorly differentiated thyroid carcinoma (PDTC) is a kind of follicular-derived malignancy, which is prone to recurrence and distant metastasis. Here, we report a rare case of the coexistence of PTC, ATC-SCC subtype and PDTC.

          Case Description

          We herein report a case of 69-year-old female who initially presented with a history of left neck mass for one month. Comprehensive auxiliary examinations and postoperative pathology confirmed the diagnosis of PTC combined with ATC-SCC subtype, and PDTC. Total thyroidectomy with radical left cervical lymph node dissection was performed, followed by thyroid-stimulating hormone (TSH) suppressive therapy, 131I, radiotherapy and chemotherapy. The patient showed no tumor recurrence or metastasis after a 5-month postoperative follow-up.

          Conclusions

          The simultaneous occurrence of PTC, ATC-SCC subtype, and PDTC is extremely rare in clinical terms or literature reports. The treatment has not been standardized, and early radical surgery is the first choice. In addition, the combination of adjuvant therapies such as TSH suppressive therapy, radiotherapy, chemotherapy and 131I may further improve the prognosis of the patient.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.

          Poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) are rare and frequently lethal tumors that so far have not been subjected to comprehensive genetic characterization.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Global Burden of Thyroid Cancer From 1990 to 2017

            Key Points Question What were the epidemiologic patterns and variation in the trends of thyroid cancer worldwide from 1990 to 2017? Findings In this cross-sectional study covering data on incidence, deaths, and disability-adjusted life-years and their temporal trends from 195 countries and 21 regions, increasing trends of thyroid cancer burden were observed, with significant differences by sex, region, country, age, and sociodemographic index. Almost half of the thyroid cancer burden was noted in Southern and Eastern Asia, and a third of patients with thyroid cancer resided in countries with a high sociodemographic index. Meaning This study suggests an increasing global burden of thyroid cancer; the geographic disparities may provide support for cancer health care planning and resource allocation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer.

              Anaplastic thyroid cancer (ATC) is a rare but highly lethal form of thyroid cancer. Rapid evaluation and establishment of treatment goals are imperative for optimum patient management and require a multidisciplinary team approach. Here we present guidelines for the management of ATC. The development of these guidelines was supported by the American Thyroid Association (ATA), which requested the authors, members the ATA Taskforce for ATC, to independently develop guidelines for ATC. Relevant literature was reviewed, including serial PubMed searches supplemented with additional articles. The quality and strength of recommendations were adapted from the Clinical Guidelines Committee of the American College of Physicians, which in turn was developed by the Grading of Recommendations Assessment, Development and Evaluation workshop. The guidelines include the diagnosis, initial evaluation, establishment of treatment goals, approaches to locoregional disease (surgery, radiotherapy, systemic therapy, supportive care during active therapy), approaches to advanced/metastatic disease, palliative care options, surveillance and long-term monitoring, and ethical issues including end of life. The guidelines include 65 recommendations. These are the first comprehensive guidelines for ATC and provide recommendations for management of this extremely aggressive malignancy. Patients with stage IVA/IVB resectable disease have the best prognosis, particularly if a multimodal approach (surgery, radiation, systemic therapy) is used, and some stage IVB unresectable patients may respond to aggressive therapy. Patients with stage IVC disease should be considered for a clinical trial or hospice/palliative care, depending upon their preference.
                Bookmark

                Author and article information

                Journal
                AME Case Rep
                AME Case Rep
                ACR
                AME Case Reports
                AME Publishing Company
                2523-1995
                07 April 2024
                2024
                : 8
                : 47
                Affiliations
                [1 ]Qinghai University College of Clinical Medicine , Xining, China;
                [2 ]deptDepartment of Oncology Surgery , Qinghai University Affiliated Hospital , Xining, China;
                [3 ]deptDepartment of Head and Neck Surgery , Hubei Cancer Hospital , Wuhan, China
                Author notes

                Contributions: (I) Conception and design: Z Ma, Y Maimaiti; (II) Administrative support: D Ma; (III) Provision of study materials or patients: Z Ma; (IV) Collection and assembly of data: Y Zhang, Q Liu; (V) Data analysis and interpretation: Y Zhang, Q Liu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

                [#]

                These authors contributed equally to this work.

                Correspondence to: Zhijun Ma, MD. Department of Oncology Surgery, Qinghai University Affiliated Hospital, No. 29 Tongren Road, Chengxi District, Xining 816000, China. Email: mzjfamai@ 123456163.com ; Yusufu Maimaiti, MD. Department of Head and Neck Surgery, Hubei Cancer Hospital, No. 116 Zhuodaoquan South Road, Hongshan District, Wuhan 430000, China. Email: docyusufu@ 123456163.com .
                Author information
                https://orcid.org/0009-0000-7214-1978
                https://orcid.org/0009-0006-9518-4288
                Article
                acr-08-23-192
                10.21037/acr-23-192
                11071005
                38711906
                7c83023d-52fa-48eb-be50-17b796caa4d4
                2024 AME Case Reports. All rights reserved.

                Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

                History
                : 06 November 2023
                : 25 January 2024
                Funding
                Funded by: the National Natural Science Foundation of China
                Award ID: Nos. 82060485
                Award ID: 82160570
                Categories
                Case Report

                papillary thyroid carcinoma (ptc),squamous cell carcinoma subtype (scc subtype),poorly differentiated thyroid carcinoma (pdtc),treatment,case report

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content472

                Most referenced authors180